Sodium Phosphate, Dibasic, Anhydrous
drugOn this page
Also known as AcetestDisodium acid phosphateDisodium phosphateanhydrousE-339(II)Exsiccated sodium phosphateFEMA NO. 2398INS NO.339(II)INS-339(II)Neutral sod phosSecondary sodium phosphateSodium monohydrogen phosphateSodium orthophosphateSodium phosphateSodium phosphate component of navstelSodium phosphate dibasicdibasic anhydrousdibasicanhydrous component of osmoprepanhydrous component of visicol
Summary
Sodium Phosphate, Dibasic, Anhydrous (CHEMBL1060) is an approved small molecule (ATC B05XA09) targeting P2RX4 and SLC6A4; indicated across 3 conditions including constipation disorder and dry eye syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: B05XA09 (+3 more)
- Targets: 2 (P2RX4, SLC6A4)
- Indications: 3 conditions
- Clinical trials: 9
- Chemistry: HO4P.2Na
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1060 |
| Name | Sodium Phosphate, Dibasic, Anhydrous |
| Type | Small molecule |
| Max phase | 4 |
| ChEBI | CHEBI:34683 |
| ATC | B05XA09, A06AG01, V03AG05, A06AD17 |
| Molecular formula | HO4P.2Na |
| InChIKey | BNIILDVGGAEEIG-UHFFFAOYSA-L |
SMILES: O=P([O-])([O-])O.[Na+].[Na+]
Also known as: Acetest, Disodium acid phosphate, Disodium phosphate, anhydrous, E-339(II), Exsiccated sodium phosphate, FEMA NO. 2398, INS NO.339(II), INS-339(II), Neutral sod phos, Secondary sodium phosphate, Sodium monohydrogen phosphate
Parent form; salt/anhydrous children: CHEMBL2107525, CHEMBL2107560
Patent coverage: 132,949 distinct patent families (305,151 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 197,575 (65%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| P2RX4 | P2X4 | Antagonist | 6 | 1.2% | Q99571 |
| SLC6A4 | SERT | Inhibition | 10.1 | 0.7% | P31645 |
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Carbonic anhydrase 4, Sodium-dependent phosphate transport protein 2A.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CA4 | 5.01 | Ki | 9800 | nM | CHEMBL_ACT_1458613 |
Target pathways
Aggregated over 2 target gene(s): P2RX4, SLC6A4.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Neurotransmitter clearance | 1 | SLC6A4 |
| Transmission across Chemical Synapses | 1 | SLC6A4 |
| Neuronal System | 1 | SLC6A4 |
| Elevation of cytosolic Ca2+ levels | 1 | P2RX4 |
| Serotonin clearance from the synaptic cleft | 1 | SLC6A4 |
| Platelet homeostasis | 1 | P2RX4 |
| SLC-mediated transport of neurotransmitters | 1 | SLC6A4 |
| Purinergic signaling in leishmaniasis infection | 1 | P2RX4 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| membrane depolarization | 2 |
| tissue homeostasis | 1 |
| regulation of sodium ion transport | 1 |
| response to ischemia | 1 |
| signal transduction | 1 |
| regulation of blood pressure | 1 |
| positive regulation of calcium ion transport into cytosol | 1 |
| negative regulation of cardiac muscle hypertrophy | 1 |
| sensory perception of pain | 1 |
| calcium-mediated signaling | 1 |
| positive regulation of prostaglandin secretion | 1 |
| response to ATP | 1 |
| monoatomic ion transmembrane transport | 1 |
| response to fluid shear stress | 1 |
| purinergic nucleotide receptor signaling pathway | 1 |
Indications & clinical
Indications
3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| constipation disorder | 4 | MONDO:0002203 | HP:0002019 |
| dry eye syndrome | 2 | MONDO:0006733 | EFO:1000906 |
| Parkinson disease | 1 | MONDO:0005180 | MONDO:0005180 |
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE4 | 2 |
| PHASE3 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00410215 | PHASE4 | COMPLETED | A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy |
| NCT03817788 | PHASE4 | COMPLETED | Randomized Controlled Trail of Polyethylene Glycol vs Sodium Phosphate for Colonic Cleansing of Colonoscopy |
| NCT01840553 | PHASE3 | COMPLETED | Efficacy and Safety Study of Sodium Phosphate Tablets vs PEG for Bowel Cleansing |
| NCT05726097 | PHASE3 | COMPLETED | Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure |
| NCT01398098 | PHASE2 | COMPLETED | Measurement of Gastric Emptying During and After COLOKIT® Intake |
| NCT05147909 | Not specified | RECRUITING | Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity |
| NCT00558376 | Not specified | TERMINATED | Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy |
| NCT02822131 | Not specified | COMPLETED | Phosphate in Blood Pressure Regulation |
| NCT04316858 | Not specified | COMPLETED | Randomized Trial Comparing Carbonated Drink With Water as a Solvent for Colonoscopy Solution |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
447 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| PAROXETINE | ChEMBL + PubChem | Phase 4 (approved) | P2RX4, SLC6A4 |
| DULOXETINE | ChEMBL | Phase 4 (approved) | P2RX4, SLC6A4 |
| CRIZOTINIB | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| GENTIAN VIOLET | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| OLODATEROL | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| TADALAFIL | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| TAFENOQUINE | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| UMECLIDINIUM | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| ACETOPHENAZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ACRIVASTINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ALECTINIB | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ALLOPURINOL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMBENONIUM | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMOXAPINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMPHOTERICIN B | ChEMBL | Phase 4 (approved) | SLC6A4 |
| APOMORPHINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ARFORMOTEROL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ASENAPINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ATOMOXETINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ATRACURIUM | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AZATHIOPRINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AZELASTINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BALSALAZIDE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BENFLUOREX | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BENZPHETAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BENZTROPINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BENZYDAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BEPRIDIL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BOSUTINIB | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BREXPIPRAZOLE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BROMHEXINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BROMODIPHENHYDRAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BROMPERIDOL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BROMPHENIRAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BUPROPION | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BUTENAFINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CABERGOLINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CALCIPOTRIENE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CALCITRIOL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CANAGLIFLOZIN | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CARBINOXAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CARIPRAZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CEFONICID | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CELECOXIB | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CETIRIZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORHEXIDINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORPHENIRAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORPHENTERMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORPROTHIXENE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CINACALCET | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CINNARIZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CISAPRIDE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CITALOPRAM | ChEMBL | Phase 4 (approved) | SLC6A4 |
Related Atlas pages
- Genes: P2RX4, SLC6A4
- Diseases: constipation disorder
- Drugs: Paroxetine, Duloxetine, Crizotinib, Olodaterol, Tadalafil, Tafenoquine, Umeclidinium, Acetophenazine, Acrivastine, Alectinib, Allopurinol, Ambenonium, Amiodarone, Amitriptyline, Amoxapine, Amphotericin B, Apomorphine, Arformoterol, Aripiprazole, Asenapine, Astemizole, Atomoxetine, Atracurium, Azathioprine, Azelastine, Balsalazide, Bazedoxifene, Benfluorex, Benzphetamine, Benztropine, Benzydamine, Bepridil, Bosutinib, Brexpiprazole, Bromhexine, Bromodiphenhydramine, Bromperidol, Brompheniramine, Bupropion, Butenafine, Cabergoline, Calcipotriene, Calcitriol, Canagliflozin, Carbinoxamine, Cariprazine, Carvedilol, Cefonicid, Celecoxib, Cetirizine, Chlorhexidine, Chlorpheniramine, Chlorphentermine, Chlorpromazine, Chlorprothixene, Cinacalcet, Cinnarizine, Cisapride, Citalopram